Business
Altimmune to Participate in the Citizens Life Sciences Conference
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows: Conference:Citizens Life Sciences ConferenceDate/Time:Wednesday, May 7, 2025, at 9:30 a.m. EDT The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. Ab
About this update from Altimmune, Inc.
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows: The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 [email protected] Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 [email protected] Media Contact: Jason Spark Inizio Evoke, Biotech Phone: 619-849-6005 [email protected] This press release was published by a CLEAR® Verified individual.